Alpha-1-antitrypsin Deficiency

Professor Kalsheker is the Head of Division and Co-director of the Institute of Genetics and teaches in the School of Life Sciences at the University of Nottingham. His work is focused on the study of humoral control of genes of the serine proteinase inhibitor family which regulate key biological pathways and how functional genetic variants contribute to complex diseases such as chronic lung disease. Professor Stockley has a longstanding interest in chronic obstructive pulmonary disease (COPD) with special reference to airway inflammation, proteinases and anti-proteinases, and especially the role of the neutrophils, bacteria and exacerbations. His research focuses on investigating the factors governing neutrophil differentiation, activation and recruitment as processes that determine the degree of tissue damage resulting in the establishment and progression of chronic lung disease.

1. Historical perspective2. The Swedish AAT screening study: What we have learnt-from birth through to young middle age3. Gene regulation4. AAT variants5. AAT structure and function6. Novel biological functions of A1AT7. AATD and lung disease8. Alpha-1-Antitrypsin Deficiency Liver Disease9. AATD epidemiological studies and other AATD associated diseases10. THORACIC CT IMAGING IN AATD11. Animal models of alpha-1 antitrypsin deficiency12. Establishing European Registries for AATD and clinical trials for lung disease13. Establishing the USA Registry: logistics, impact and early clinical trials14. Gene therapy15. The future of AAT research